Ani Pharmaceuticals Inc (ANIP) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Competitors, else..
 
Ani Pharmaceuticals Inc  (NASDAQ: ANIP)
 

Ani Pharmaceuticals Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ANIP Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q2 MRQ) 25.87 % 12.22 % 8.91 % 10.9 %
Q / Q Revenue Growth (Q2 MRQ) 12.04 % -2.93 % -3.28 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM) 30.9 % 9.25 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q2 TTM) 5.92 % 2.69 % 2.03 % 2.61 %
Revenue 5 Year Average Growth 33.48 % 7.41 % 8.65 % 10.59 %


ANIP's Growth Comparisons in II. Quarter 2026




Strong but slowing Revenue rise by Ani Pharmaceuticals Inc of 25.87% year on year , in the second quarter 2026 to 266 millions, was higher than the 12.22% rise in the Major Pharmaceutical Preparations industry, and 8.91% growth in the Healthcare sector. Comparing the second quarter sales growth, both Major Pharmaceutical Preparations industry and Ani Pharmaceuticals Inc outperformed 10.9% overall market increase.

Top-line improved by 12.04% from the first quarter. Looking into annual sales rise of 33.48%, and S & P 500's average yearly sales growth is 10.59% over the five years, including only Businesses with the second quarter 2026 Results. Ani Pharmaceuticals Inc grew faster than the market.

ANIP Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Sales of Cortrophin Gel
-
-
Sales of ILUVIEN and YUTIQ
-
-
Total sales of rare disease pharmaceutical products
-
-
Sales of Established Brands
-
-
Sales of Established Brand Royalties and Other Revenues
-
-
Total Sales of Rare Disease and Brands
-
-
Sales of generic pharmaceutical products
-
-
Sales of Generic Other Revenues
-
-
Total Sales of Generics and Other
-
-
Brands
-9.81 %
-3.47 %
Generics and Other
122.77 %
92.16 %
Rare Disease and Brands
150.63 %
128.97 %
Total
25.87 %
12.04 %


Growth Rates of ANIP's Income in the second quarter 2026


ANIP Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q2 MRQ) 191.25 % -8.88 % 4.62 % 97.6 %
Sequential Operating Income Change (Q2 MRQ) 4.04 % -4.52 % 0.89 % 48.13 %
Y / Y Operating Income Growth (Q2 TTM) 889.89 % 30.63 % 30.73 % 40.67 %
Sequential Operating Income Growth (Q2 TTM) 21.46 % -2.27 % 4.82 % 20.86 %
Operating Income 5 Year Avg. Change - 14.39 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ) 169.04 % -34.9 % -25.98 % 90.69 %
Sequential Income from Cont. Ops. Change (Q2 MRQ) -22.01 % -2.61 % -66.16 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q2 TTM) 580.51 % 6.3 % 2.68 % 57.33 %
Sequential Income from Cont. Ops. Change (Q2 TTM) 15.54 % -10.02 % -5.02 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change - -0.55 % 0.17 % -28.52 %

ANIP Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q2 MRQ) 169.04 % -35.09 % -26.26 % 90.69 %
Q / Q Net Income Growth (Q2 MRQ) -22.01 % 2.87 % -0.77 % 27.07 %
Y / Y Net Income Change (Q2 TTM) - 5.21 % 15.51 % 57.33 %
Sequential Net Income Change (Q2 TTM) 15.68 % -10.17 % -6.72 % 18.65 %
Net Income 5 Year Avg. Growth - 14.55 % 9.21 % 22.96 %

ANIP's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ) 194.59 % -40.27 % -25.98 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ) -16.79 % -7.72 % -66.16 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q2 TTM) 16.82 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth - -10.78 % 0.17 % -28.52 %



ANIP EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q2 MRQ) 191.67 % -40.45 % -26.26 % -28.52 %
Q / Q EPS Net Growth (Q2 MRQ) -17.97 % -2.53 % -0.77 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q2 TTM) 16.83 % - - 4.93 %
EPS Net 5 Year Avg. Change - 14.55 % 9.21 % 22.96 %



Despite the -40.45% decline in Major Pharmaceutical Preparations industry, Ani Pharmaceuticals Inc showed impressive surge in EPS in the second quarter by 191.67% from the same quarter a year ago, to $1.05, Healthcare sector dropped -26.26%. Despite modest earnings per share in the Major Pharmaceutical Preparations industry and ind the Healthcare sector, Ani Pharmaceuticals Inc reported above average market earnings per share growth.

Comparing the company's EPS to the first quarter results, income per share were lower by -17.97% . On the annual basis, average annual income per share growth for Ani Pharmaceuticals Inc is 33.48%, while S & P 500's including only Businesses with the second quarter 2026 financial reports, average yearly income per share growth is 22.96% over the past five years.

ANIP Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ) -22.19 % 25.53 % 48.49 % 48.62 %
Sequential Free Cash Flow Change (Q2 MRQ) 13.95 % -42.37 % -46.96 % 34.18 %
Y / Y Free Cash Flow Change (Q2 TTM) 60.37 % 11.91 % 18.61 % 60.27 %
Sequential Free Cash Flow Change (Q2 TTM) -8.36 % 3.24 % 5.39 % 15.75 %
Free Cash Flow 5 Year Avg. Change - 1.86 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q2 MRQ) - - - 216.68 %
Y / Y Net Cash Flow Change (Q2 TTM) - - - 209.43 %
Sequential Net Cash Flow Change (Q2 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change - 29.88 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ) -55.8 % 11.25 % 8.23 % 120.03 %
Sequential Capital Expenditures Change (Q2 MRQ) -73.03 % -25.6 % -22.09 % 36.87 %
Y / Y Capital Expenditures Change (Q2 TTM) -36.72 % 16.65 % 7.87 % 109.38 %
Sequential Capital Expenditures Change (Q2 TTM) -14.94 % 2.92 % 1.6 % 23.05 %
Capital Expenditures 5 Year Avg. Change -12.86 % 8.94 % 9.18 % 14.72 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.